Leerink Partnrs Brokers Decrease Earnings Estimates for BPMC

Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) - Equities research analysts at Leerink Partnrs cut their FY2025 earnings per share estimates for shares of Blueprint Medicines in a report released on Wednesday, February 5th. Leerink Partnrs analyst A. Berens now anticipates that the biotechnology company will earn ($1.24) per share for the year, down from their prior forecast of ($0.99). The consensus estimate for Blueprint Medicines' current full-year earnings is ($3.63) per share.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%.

Other equities analysts have also issued research reports about the stock. Guggenheim reiterated a "buy" rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. UBS Group assumed coverage on shares of Blueprint Medicines in a report on Thursday, October 24th. They issued a "neutral" rating and a $88.00 price objective for the company. JMP Securities restated a "market outperform" rating and issued a $125.00 target price on shares of Blueprint Medicines in a research report on Wednesday, January 15th. StockNews.com raised Blueprint Medicines from a "sell" rating to a "hold" rating in a research note on Friday, November 8th. Finally, Wedbush reissued an "outperform" rating and issued a $128.00 price objective (up previously from $124.00) on shares of Blueprint Medicines in a research note on Thursday. One analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Blueprint Medicines currently has a consensus rating of "Moderate Buy" and a consensus price target of $123.83.

Blueprint Medicines Stock Performance

Blueprint Medicines stock traded down $8.37 during mid-day trading on Monday, hitting $95.19. 2,724,491 shares of the company's stock traded hands, compared to its average volume of 1,036,841. Blueprint Medicines has a one year low of $72.24 and a one year high of $121.90. The company has a market cap of $6.05 billion, a PE ratio of -45.11 and a beta of 0.62. The firm has a 50 day moving average price of $99.65 and a 200 day moving average price of $94.77. The company has a quick ratio of 3.27, a current ratio of 3.32 and a debt-to-equity ratio of 1.09.

Institutional Investors Weigh In On Blueprint Medicines

Large investors have recently modified their holdings of the stock. Quarry LP bought a new position in Blueprint Medicines during the 3rd quarter valued at about $32,000. R Squared Ltd bought a new stake in Blueprint Medicines during the 4th quarter worth about $51,000. Covestor Ltd lifted its position in shares of Blueprint Medicines by 206.7% during the third quarter. Covestor Ltd now owns 598 shares of the biotechnology company's stock worth $55,000 after purchasing an additional 403 shares in the last quarter. Headlands Technologies LLC bought a new stake in shares of Blueprint Medicines during the fourth quarter valued at approximately $65,000. Finally, Asset Management One Co. Ltd. acquired a new position in Blueprint Medicines during the 4th quarter worth $88,000.

Insider Buying and Selling

In other Blueprint Medicines news, insider Ariel Hurley sold 1,819 shares of the firm's stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $93.26, for a total value of $169,639.94. Following the completion of the sale, the insider now owns 14,967 shares in the company, valued at approximately $1,395,822.42. This trade represents a 10.84 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey W. Albers sold 15,161 shares of the firm's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $109.53, for a total value of $1,660,584.33. Following the completion of the transaction, the director now directly owns 152,396 shares of the company's stock, valued at approximately $16,691,933.88. This trade represents a 9.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 49,851 shares of company stock valued at $4,984,696. Company insiders own 4.21% of the company's stock.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.